Mr. Gallagher is a serial biotechnology entrepreneur with over 33 years of experience in the biotechnology and pharmaceutical industry as an executive, company founder, investor and board member. He is currently President & CEO of Alessa Therapeutics. Alessa is a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early treatment of prostate cancer. He previously served as Co-Founder, President & Board Member of Zentalis Pharmaceuticals (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. He also served as Chief Business Officer of Retrosense Therapeutics, a clinical stage gene therapy company focused on inherited retinal disorders, through their acquisition by Allergan.

Cam currently serves on the board of directors for Opus Genetics (Nasdaq: IRD), SelectION, Immusoft and UC San Diego Moores Cancer Center. His previous board roles include VelosBio (acquired by Merck for $2.8B), Retrosense Therapeutics (acquired by Allergan for up to $580M) and Zentalis Pharma (Nasdaq: ZNTL). Cam received his B.B.A. from Ohio University and his M.B.A. from the University of San Diego focusing on finance and marketing.

Mr. Fallace (Dave) is a Managing Partner and Co-Founder of Cure Ventures. He has made investments in venture capital and alternative asset funds for over 20 years. He served as a member of the investment committee of several large multibillion-dollar firms overseeing alternative investment portfolios. Across these portfolios he made investments as a limited partner and as a founding investor in start-ups.

Most recently, Dave served as an advisor for the biotech venture capital fund Polaris Partners where he evaluated Biotechnology and Health Care Information Technologies investments. During this period, he also served as an Expert-in-Resident program at Harvard University’s Office of Technology Development. Prior to Polaris, he served as a Managing Director and member of the investment committee heading the $2.5 billion diversifying strategies at TIFF Investment Management.

From 2013 to 2016, Dave served as the Director of Investments leading the $10 billion Special Opportunities program at the Alaska Permanent Fund Corporation. He spearheaded their direct venture investing serving as a board observer at Juno Therapeutics (Acquired by Celgene), and Denali Therapeutics (NASDAQ: DNLI).

Starting in 2000, Dave worked at GF Private Equity Group managing private equity and hedge fund portfolios in addition to investing in direct venture capital transactions. He served on the board or board observer of Ahura (Acquired Thermo Fisher), Alfalight (Acquired Gooch & Housego), Kotura (Acquired Mellanox), Pathscale (Acquired QLogic), Teros (Acquired Citrix), and Impinj (NASDAQ:PI).

Dave received his B.A. from Stony Brook University and his M.B.A. and J.D. from the State University of New York at Buffalo focusing on tax and financial structuring and is a member of the New York Bar.

Dr. Tartaglia (Lou) is a Managing Partner and Co-Founder of Cure Ventures. Lou’s career spans more than 30 years demonstrating scientific and therapeutic product project leadership within the biotech industry as well as investment leadership within multiple venture capital firms. His experience and skills as a rigorous scientist have manifested itself across a wide array of functional areas, allowing him to serve with distinction within the C-Suite in numerous biotech start-ups.

In 2016 Lou served as Head of 4:59, 5AM Venture’s internal de novo new company formation initiative. In that first year he led the formation of Entrada Therapeutics (NASDAQ: TRDA) and then served as interim CEO for its first year. Lou subsequently transitioned into a 5AM Venture Partner role where he has taken CEO roles at start-ups.

From 2007 to 2014 Lou served as a Partner at Third Rock Ventures where he played an integral role in the overall scientific diligence, formation, and development of its portfolio companies. While a Partner at Third Rock he played crucial roles in starting many of Third Rock’s most successful portfolio companies including as Chief Scientific Officer of Editas (NASDAQ: EDIT), Rhythm (NASDAQ: RYTM) and Agios (NASDAQ: AGIO) for the first year of operations. Beyond Third Rock he also served as Chief Executive Officer of Solstice Biologics and General Manager at GeneLogic.

Lou was formerly the first employee of and Vice President at the start-up Millennium Pharmaceuticals where he was responsible for the discovery and development of multiple therapeutic programs, which was later acquired for $8.7 Billion by Takeda Pharmaceuticals.

Lou completed his postdoctoral work at Genentech in the laboratory of Dr. David Goeddel. He received his Ph.D. in Biochemistry at the University of California, Berkeley in the laboratory of Dr. Bruce Ames and his B.S. in Chemistry at the State University of New York at Albany.